THNR holdings
All 21 positions of Amplify Weight Loss Drug & Treatment ETF.
Positions
21
Top 10 weight
60.2%
Effective holdings
17.5
1 / sum of squared weights
In stocks
97.4%
In bonds
0.0%
Outside the US
40.6%
Asset mix
Sectors
68% of stocks classifiedCountries
Holdings
| # | Holding | Type | Weight | Value | Shares / par | Country |
|---|---|---|---|---|---|---|
| 1 | NVONovo-Nordisk A/S | Equity | 9.76% | $426K | 8,881 | DK |
| 2 | LLYEli Lilly & Co. | Equity | 9.26% | $404K | 337 | US |
| 3 | SRRKScholar Rock Holding Corporation Common Stock | Equity | 5.71% | $249K | 4,531 | US |
| 4 | HIMSHims & Hers Health, Inc. | Equity | 5.57% | $243K | 7,013 | US |
| 5 | VKTXViking Therapeutics, Inc | Equity | 5.49% | $240K | 6,142 | US |
| 6 | ABBVABBVIE INC. | Equity | 5.20% | $227K | 901 | US |
| 7 | ARWRArrowhead Research Corporation | Equity | 5.08% | $222K | 2,722 | US |
| 8 | Innovent Biologics Inc | Equity | 5.00% | $218K | 21,500 | CN |
| 9 | AMGNAmgen Inc | Equity | 4.58% | $200K | 552 | US |
| 10 | Chugai Pharmaceutical Co Ltd | Equity | 4.57% | $199K | 4,300 | JP |
| 11 | MRKMerck & Co., Inc. | Equity | 4.56% | $199K | 1,550 | US |
| 12 | AstraZeneca PLC | Equity | 4.56% | $199K | 1,049 | GB |
| 13 | Roche Holding AG | Equity | 4.52% | $197K | 478 | CH |
| 14 | REGNRegeneron Pharmaceuticals Inc | Equity | 4.49% | $196K | 314 | US |
| 15 | CSPC Pharmaceutical Group Ltd | Equity | 4.48% | $196K | 220,000 | CN |
| 16 | PFEPfizer Inc. | Equity | 4.39% | $192K | 7,957 | US |
| 17 | Zealand Pharma A/S | Equity | 3.49% | $152K | 3,434 | DK |
| 18 | KLRAKailera Therapeutics, Inc. Common Stock | Equity | 2.46% | $107K | 4,864 | US |
| 19 | Jiangsu Hengrui Pharmaceutical | Equity | 2.26% | $99K | 13,400 | CN |
| 20 | Invesco Government & Agency Po | Cash | 2.01% | $88K | 87,847 | US |
| 21 | Hanmi Pharm Co Ltd | Equity | 2.00% | $87K | 341 | KR |
Find which other funds hold a stock by opening it and choosing "ETFs holding".
Position changes between reports
| Action | Holding | Weight before | Weight after | Shares vs flows | Between reports |
|---|---|---|---|---|---|
| New position | HIMSHims & Hers Health Inc | — | 5.57% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | Shionogi & Co Ltd | 4.46% | — | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | SRRKScholar Rock Holding Corp | 2.37% | 5.71% | +141.8% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | VKTXViking Therapeutics Inc | 2.21% | 5.49% | +133.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| New position | KLRAKailera Therapeutics Inc | — | 2.46% | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | LLYEli Lilly & Co | 11.56% | 9.26% | −30.9% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | NVONovo Nordisk A/S | 11.89% | 9.76% | −29.3% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Exit | GPCRStructure Therapeutics Inc | 2.02% | — | — | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | Zealand Pharma A/S | 1.74% | 3.49% | +131.9% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | AMGNAmgen Inc | 6.27% | 4.58% | −20.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | Jiangsu Hengrui Pharmaceutical | 1.23% | 2.27% | +131.2% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | Hanmi Pharm Co Ltd | 1.28% | 2.00% | +130.9% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | Innovent Biologics Inc | 4.43% | 5.00% | +35.3% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | CSPC Pharmaceutical Group Ltd | 5.03% | 4.48% | +30.8% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | PFEPfizer Inc | 4.62% | 4.39% | +24.7% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Decrease | ARWRArrowhead Pharmaceuticals Inc | 4.96% | 5.08% | −11.4% | Mar 31, 2026 → Jun 30, 2026 SEC |
| Increase | AstraZeneca PLC | 4.66% | 4.56% | +14.5% | Mar 31, 2026 → Jun 30, 2026 SEC |
Share-count changes are measured after removing what creations and redemptions explain.
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.